[go: up one dir, main page]

WO2004047806A1 - Procede permettant d'obtenir des particules de dimensions bacteriennes - Google Patents

Procede permettant d'obtenir des particules de dimensions bacteriennes Download PDF

Info

Publication number
WO2004047806A1
WO2004047806A1 PCT/HU2003/000007 HU0300007W WO2004047806A1 WO 2004047806 A1 WO2004047806 A1 WO 2004047806A1 HU 0300007 W HU0300007 W HU 0300007W WO 2004047806 A1 WO2004047806 A1 WO 2004047806A1
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
particles
changing
solution
size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2003/000007
Other languages
English (en)
Inventor
István HORVÁTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2003202716A priority Critical patent/AU2003202716A1/en
Priority to EP03701627A priority patent/EP1567128A1/fr
Publication of WO2004047806A1 publication Critical patent/WO2004047806A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Definitions

  • Both methods can only ameliorate symptoms, but can not solve the problem of deficiency of cholesterol metabolism. Removal of cholesterol from the blood stream still presents a problem.
  • ordinary, common cholesterol in trade is specially purified for the process, during said process a saturated solution is produced in an organic solvent at 56-90 °C, -then said solution is crystallized by changing the temperature, then crystals are collected on a sterile filter, dried and said crystalls are solved in another solvent and a saturated solution is produced at 56-90 °C then it is crystallized by changing the temperature,
  • Particles produced according to the process according to the invention can be characterized by that,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé permettant de produire des particules de dimensions bactériennes à partir du cholestérol, ainsi que les particules conçues au moyen du procédé permettant de stimuler la production d'anticorps anti-cholestérol et au moyen du procédé de production de particules de dimensions des micro-coccus (100-500 nm) conçues pour immuniser l'utilisation du cholestérol à degré de pureté élevé. L'invention concerne également un procédé de production de particules de dimensions bactériennes à partir du cholestérol consistant à chauffer une solution supersaturée à un niveau de saturation, une solution presque saturée étant ainsi obtenue. Ce procédé est caractérisé en ce que des conditions de production des membranes liquides disposées sous la forme de cristaux à partir des molécules du cholestérol sont créées par changement du cholestérol dans la solution de cholestérol insaturée, au moyen d'un changement continu et égal du rapport de combinaison de solvants polaires et non polaires, puis par émission d'une énergie physique d'amplitude déterminée, les membranes étant transformées en particules de structure caractéristique pouvant être observée au microscope. L'invention concerne enfin les particules produites, de préférence, au moyen du procédé selon l'invention, lequel est caractérisé en ce que la membrane de surface de la particule de dimensions des micro-coccus constitue le cholestérol à degré de pureté élevé.
PCT/HU2003/000007 2002-11-26 2003-01-31 Procede permettant d'obtenir des particules de dimensions bacteriennes Ceased WO2004047806A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003202716A AU2003202716A1 (en) 2002-11-26 2003-01-31 Process for obtaining bacterium-size particles
EP03701627A EP1567128A1 (fr) 2002-11-26 2003-01-31 Procede permettant d'obtenir des particules de dimensions bacteriennes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0204064 2002-11-26
HU0204064A HUP0204064A2 (hu) 2002-11-26 2002-11-26 Eljárás koleszterinből nyerhető baktérium méretű partikulák előállítására, valamint az eljárással előállított partikula

Publications (1)

Publication Number Publication Date
WO2004047806A1 true WO2004047806A1 (fr) 2004-06-10

Family

ID=89980957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2003/000007 Ceased WO2004047806A1 (fr) 2002-11-26 2003-01-31 Procede permettant d'obtenir des particules de dimensions bacteriennes

Country Status (4)

Country Link
EP (1) EP1567128A1 (fr)
AU (1) AU2003202716A1 (fr)
HU (1) HUP0204064A2 (fr)
WO (1) WO2004047806A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083100A1 (fr) * 2001-04-11 2002-10-24 Horvath Istvan Liposomes constitues essentiellement de cholesterol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083100A1 (fr) * 2001-04-11 2002-10-24 Horvath Istvan Liposomes constitues essentiellement de cholesterol

Also Published As

Publication number Publication date
HUP0204064A2 (hu) 2005-07-28
EP1567128A1 (fr) 2005-08-31
AU2003202716A1 (en) 2004-06-18
HU0204064D0 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
EP0310716B1 (fr) Produit, préparation et méthode pour le traitement des allergies
NL192088C (nl) Cytotoxisch produkt.
DE69738140T2 (de) Hapten-träger konjugate zur verwendung in der drogentherapie und verfahren zu deren herstellung
AU737980B2 (en) Novel polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
JPH04502910A (ja) 粘着性薬物送達組成物
WO1997005267A2 (fr) Apport de polynucleotides dans les muqueuses
CH644521A5 (de) Therapeutisches immunosuppressives mittel und verfahren zu dessen herstellung.
ES2425315A2 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
LT5987B (lt) Farmacinės kompozicijos
CN118027062B (zh) 一种雷帕霉素前药及其纳米制剂的制备和应用
US3541201A (en) Novel sodium chloride encapsulated injectionable substances
CA2067210A1 (fr) Condensation interfaciale de composes bioactifs et les composes specifiques d'un siege et leurs conjugues
Thakur et al. Recent trends in targeted drug delivery
EP1567128A1 (fr) Procede permettant d'obtenir des particules de dimensions bacteriennes
CN113648288A (zh) 一种红细胞膜包被功能性分子的纳米复合物、制法及应用
CN106267198B (zh) 靶向光热治疗联合免疫治疗抗肿瘤复合制剂及其制备方法与应用
US20230381183A1 (en) USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA
WO2002083100A1 (fr) Liposomes constitues essentiellement de cholesterol
Marusić-Galesić et al. Cellular immune response to the antigen administered as an immune complex in vivo
JPWO2008026781A1 (ja) 逆標的化脂質小胞体
JPS60224634A (ja) 吸入アレルゲンを含有するアレルギー治療用リポソーム
JPH05501258A (ja) オキシダイズされたリポプロテインを使用した病状治療法及び装置
JP4331798B2 (ja) アレルゲン処方
JPS6221335B2 (fr)
RU2712212C1 (ru) Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003701627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003701627

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWR Wipo information: refused in national office

Ref document number: 2003701627

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003701627

Country of ref document: EP